Otsu/Shiga, Japan – November 5, 2012 – Takara Bio Inc. announced that it would establish a new facility in July 2013 within the grounds of its consolidated subsidiary Takara Biomedical Technology (Beijing) Co., Ltd. to manufacture anti-CD3 monoclonal antibodies and other antibodies for cancer immunotherapy in compliance with GMP (Good Manufacturing Practice). Takara Bio will invest approximately ¥150 million for this project.

 

Takara Biomedical Technology has been marketing cell culture media and gas-permeable bags for cancer immunotherapy to Chinese medical institutions. As the Chinese market of cancer immunotherapy has been expanding, the sales of these products have been rapidly growing.

 

This GMP-compliant facility will enable Takara Bio to expand the product lineup for cell therapy to establish a solid position in the growing market in China.

 

[ About Takara Bio Inc. ]

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.